SSG
ACOR

Summit Securities Group’s Acorda Therapeutics ACOR Stock Holding History

Summit Securities Group’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-12
Closed -$50K – 612
2013
Q3 		$50K Buy
+12
New +$51.7K 0.02% 185

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Summit Securities Group's ACOR Position: Q4 2013 in Review

Summit Securities Group sold out of Acorda Therapeutics (ACOR) in Q4 2013, closing a stake of 12 shares — an estimated $50K sold.

Summit Securities Group first reported a position in ACOR in Q3 2013 and held it in 1 quarter. The position peaked at $50K in Q3 2013. 163 funds tracked by Wall St. Rank hold ACOR as of Q4 2013.

  • Summit Securities Group reported no remaining Acorda Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Summit Securities Group sold 12 Acorda Therapeutics shares in Q4 2013, an estimated $50K.
  • Summit Securities Group first reported a position in Acorda Therapeutics in Q3 2013 and held it in 1 quarter.
  • Summit Securities Group's Acorda Therapeutics position peaked at $50K in Q3 2013.
  • 163 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2013.

Based on Summit Securities Group's 13F filing for Q4 2013, filed 13 Feb 2014.